Not to dwell too much on DR. BP's absence, but I a

Not to dwell too much on DR. BP's absence, but I agree with this and also it sparked something I remember from the last conference (real conference call not super stock webinar) someone asked a science question and NP said lets keep this call about investing and not science please or something to that affect(not exact wording but paraphrasing). Dr. BP is generally only there to answer science and describe how leronlimab works. So I think Dr. Lalezari is there for trial updates and possibly to handle a science question if it comes up, but I do believe this call is more about all these trials and the possible funding of these trials(***note the PR does not mention funding, but if half the indications listed were on hold because of lack of funds...but now we're going to get an update on them?...if they were still on hold whats to update? If we suddenly have money...then there is something to update and timelines to give of starting/re-initiating trials) .

disclaimer:
My thoughts only. They will be anywhere between 0 and 100% accurate. read at your own risk.